Skip to main content

Table 1 Summary of clinicopathological features of FA-DLBCL reported cases and our case

From: Fibrin-associated diffuse large B-cell lymphoma with plasmacytic differentiation: case report and literature review

Author Cases Age Sex Location Diagnosis Phenotype EBV latency Stage Adjuvant treatment Follow-up (months)
Garces et al, 2019 [7] 1 50 M Left atrial myxoma FA-DLBCL Non-GC NA Localized None 65-WER
Zanelli et al, 2019 [8] 1 75 F Adrenal pseudocyst FA-DLBCL Non-GC NA NA NA NA
Boyer et al, 2017 [4] 12 54 F Left atrial myxoma FA-DLBCL NA NA NA NA 130-WER
55 F Left atrial myxoma FA-DLBCL Non-GC Type III NA None Died 2 mo-WER
54 M Left atrial myxoma FA-DLBCL Non-GC Type III Localized None Died 26 mo-recurrent atrial mass
56 M Aortic aneurysm FA-DLBCL Non-GC Type III Localized R-CHOP × 6 24-persistent local disease
68 M Arterial thromboembolism FA-DLBCL Non-GC Type III NA R-COEP × 2 Died 10 mo-WER
71 M Aortobifemoral prosthesis FA-DLBCL Non-GC Type II-III NA None 10-WER
79 M Testicular hematoma FA-DLBCL Non-GC Type III NA None Died 17 mo-WER
25 M Subdural hematoma FA-DLBCL Non-GC Type II-III Localized None 7-WER
37 F Splenic pseudocyst FA-DLBCL Non-GC NA Localized R-CHOP × 3 32-WER
73 M Retroperitoneal pseudocyst FA-DLBCL Non-GC NA Localized R-CHOP × 6 43-WER
70 M Adrenal pseudocyst FA-DLBCL Non-GC Type III Localized None 14-WER
44 M Retroperitoneal pseudocyst FA-DLBCL Non-GC Type III Localized CHOP × 5 84-WER
Kirschenbaum et al, 2017 [5] 1 81 M Arachnoid cyst FA-DLBCL NA NA Localized R-L x NA NA
Yan et al, 2017 4 46 F Left atrial myxoma DLBCL-CI Non-GC Type III Localized None 10-WER
61 F Left atrial myxoma DLBCL-CI GC Type III Localized None 7-WER
54 M Left atrial myxoma DLBCL-CI Non-GC Type III Localized None 7-WER
46 F Left atrial myxoma DLBCL-CI Non-GC Type III Localized None 3-WER
Aguilar et al, 2015 [1] 1 52 M Left atrial myxoma FA-DLBCL Non-GC Type III Localized None 42-WER
Tapan et al, 2015 [6] 1 49 M Left atrial myxoma EBV-DLBCL Non-GC Type III Localized R-CHOP × 6 12-WER
Gruver et a., 2012 [2] 3 55 M Aortic root graft FA-DLBCL Non-GC Type III Localized R-CEOP × 8 16-WER
56 M Left atrium FA-DLBCL Non-GC Type III Localized R-CHOP × 6 8-WER
75 M Mitral valve FA-DLBCL Non-GC EBV - Localized R-CVP × 1 and R-CHOP × 6 39-WER
Svec et al, 2012 [4] 1 60 F Left atrial myxoma EBV-DLBCL Non-GC Type III Localized R-CHOP × 6 7-WER
Loong et al, 2010 [3] 4 29 M Splenic cyst DLBCL-CI Non-GC Type III Localized Rituximab × 6 6-WER
88 M Right hydrocele DLBCL-CI Non-GC Type III NA Lost to follow-up NA
70 F Left atrial myxoma DLBCL-CI Non-GC Type III Localized R-CEOP × 4 Died 5 mo-WER
78 M Knee prosthesis DLBCL-CI Non-GC Type III Localized RT × 7 84 (7 y)-WER
Present case 1 57 F Left atrial myxoma Plasmacytic FA-DLBCL Non-GC Type I NA None 1-Loss of follow-up
  1. FA-DLBCL fibrin-associated diffuse large B-cell lymphoma, DLBCL-CI DLBCL associated with chronic inflammation, Non-GC non-germinal center, GC germinal center, NA not available, WER without evidence of recurrence, R-L rituximab, lenalidomide, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, R-CVP rituximab, cyclophosphamide, vincristine and prednisone, R-COEP rituximab, cyclophosphamide, vincristine, etoposide, prednisone, R-CEOP rituximab, cyclophosphamide, etoposide, oncovin, and prednisone, RT radiotherapy